NCT03443674已完成1 期
A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 5
- 主要终点
- Safety and Tolerability: Occurrence of serious adverse events (SAEs) and/or TEAEs
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered twice weekly for 2 weeks via IP bolus injection for the treatment of patients with peritoneal malignancies, including but not limited to peritoneal carcinomatosis, malignant ascites, pseudomyxoma peritonei, and peritoneal mesothelioma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed peritoneal malignancies after failure or refusal of all approved therapies, and no better option available in the Investigator's opinion.
- •Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2 (Patients with ECOG score of 3 might be allowed to enter this trial per Investigator's judgment)
- •Life expectancy of at least 8 weeks
- •Age ≥18 years
- •Body mass index ≥17.0 kg/m2
- •Adequate hematological function, defined as:
- •Platelet count ≥ 75,000/μL
- •Prothrombin time and activated partial thromboplastin time ≤1.5 times the upper limit of normal (ULN)
- •Absolute neutrophil count ≥1,500/μL
- •Hemoglobin ≥8 g/dL (transfusion and erythropoietic agents are allowed. In case there is existence of active bleeding or other persistent condition of either increased destruction or impaired production of erythrocytes which may require repeated transfusion or erythropoietic treatment, the eligibility must be discussed with the Sponsor on a case-by-case basis prior to randomization)
- •Adequate renal function, defined as serum creatinine ≤2.0 times ULN and creatinine clearance >45 mL/minute
- •Adequate liver function, defined as:
- •Aspartate aminotransferase and alanine aminotransferase ≤3 times ULN for patients without liver metastases, or ≤5 times ULN in the presence of liver metastases
- •Bilirubin ≤1.5 times ULN, unless patient has known Gilbert's syndrome
- •Female patients of childbearing potential (excluding women who have undergone surgical sterilization or menopause. Menopause is defined as the status where no menstrual periods continue for 1 year or more without any other medical reasons), are eligible if they have negative serum pregnancy testing within 7 days prior to first dosing and are willing to use an effective method of birth control/contraception to prevent pregnancy until 6 months after discontinuation of the SCB-
- •Both men and women of reproductive potential must agree to use effective contraception during the study and for 6 months after discontinuation of the SCB-
- •Note: Contraceptive methods that are considered highly effective are, for example, total abstinence, an intrauterine device, a double barrier method (such as condom plus diaphragm with spermicide), a contraceptive implant, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release), or have a vasectomized partner with confirmed azoospermia.
排除标准
- •Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous (IV) antibiotics within 2 weeks prior to enrollment.
- •Symptoms or signs (including laboratory tests) of clinically significant concomitant hematologic, cardiovascular, pulmonary, hepatic, renal, pancreatic, or endocrine diseases.
- •Residual adverse events (AEs) > Grade 2 from previous treatment.
- •Evidence or suspicion of relevant psychiatric impairment including alcohol or recreational drug abuse.
- •Myocardial infarction within 6 months prior to treatment, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or QT/QTc interval >450 msec at baseline.
- •Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed upon repeated measures.
- •Left ventricular ejection fraction <40% as determined by echocardiography performed at screening or within 90 days prior to enrollment.
- •Prior anti-tumor therapy (chemotherapy) within 2 weeks, hormone therapy or palliative extra-abdominal radiotherapy within at least 1 week, or small-molecule targeted therapy within 5 half-lives prior to enrollment. Prior therapy with monoclonal antibody should be stopped after Investigator's judgement making sure delayed side effects will not interfere with the dose limiting toxicity (DLT) evaluation period after SCB-313 therapy.
- •Major surgery within 4 weeks prior to enrollment.
- •Patient with ileus within 30 days prior to screening.
- •Positive serology test for human immunodeficiency virus Type 1 and 2 or known history of other immunodeficiency disease.
- •Live vaccine within 2 weeks prior to enrollment.
- •Scheduled participation in another clinical study involving an investigational product or device during the course of this study.
- •Previous treatment with a TRAIL-based therapy or death receptor (DR) 4/5 agonist therapy.
- •Known or suspected hypersensitivity to any component of the SCB-
- •Any further condition which, according to the Investigator, may result in undue risk of the patient by participating in the present study.
- •Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression.
研究组 & 干预措施
SCB-313
Experimental
Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
干预措施: SCB-313 (Drug)
结局指标
主要结局
Safety and Tolerability: Occurrence of serious adverse events (SAEs) and/or TEAEs
时间窗: Up to 41 days after start of treatment
Regardless of causality or relationship to SCB-313 graded using National Cancer Institute Common Terminology Criteria for Adverse Events Version.4.03 (NCI CTCAE v4.03).
次要结局
- Immunogenicity: Occurrence of binding and neutralizing anti-SCB-313 antibodies(Up to 41 days after start of treatment)
- Pharmacokinetics (Ctrough)(Up to 12 days after start of treatment)
- Pharmacokinetics (tmax)(Up to 12 days after start of treatment)
- Pharmacokinetics ([AUC]0-24)(Up to 12 days after start of treatment)
- Pharmacokinetics (AUC0-24/D)(Up to 12 days after start of treatment)
- Pharmacokinetics ((AUC0-last))(Up to 12 days after start of treatment)
- Pharmacokinetics (Cmax/D)(Up to 12 days after start of treatment)
- Pharmacokinetics (Cmax)(Up to 12 days after start of treatment)
研究者
研究点 (5)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMMLHematologic MalignancyNCT05690425Biocity Biopharmaceutics Co., Ltd.13
终止
1 期
A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast CancerER+ / HER2- Advanced Breast CancerNCT05103826Jiangsu HengRui Medicine Co., Ltd.3
已完成
1 期
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 DiabetesDiabetes Mellitus, Type 1NCT02038764Pfizer37
已完成
1 期
A Study To Assess The Safety Of PF-06342674 In Healthy VolunteersHealthyNCT01740609Pfizer80
已完成
1 期
A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer TreatmentNeoplasmsNon-HodgkinB-CellCancerLymphomaNCT01561911Cancer Research UK29